EA200970877A1 - Композиция, пригодная для предупреждения диабета 2 типа и его осложнений у пациентов с предиабетом с резистентностью к инсулину - Google Patents

Композиция, пригодная для предупреждения диабета 2 типа и его осложнений у пациентов с предиабетом с резистентностью к инсулину

Info

Publication number
EA200970877A1
EA200970877A1 EA200970877A EA200970877A EA200970877A1 EA 200970877 A1 EA200970877 A1 EA 200970877A1 EA 200970877 A EA200970877 A EA 200970877A EA 200970877 A EA200970877 A EA 200970877A EA 200970877 A1 EA200970877 A1 EA 200970877A1
Authority
EA
Eurasian Patent Office
Prior art keywords
diabetes
complications
patients
type
insulin resistance
Prior art date
Application number
EA200970877A
Other languages
English (en)
Other versions
EA018442B1 (ru
Inventor
Клаудио Кавацца
Паоло Карминати
Original Assignee
Сигма-Тау Индустрие Фармасьютике Риуните С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сигма-Тау Индустрие Фармасьютике Риуните С.П.А. filed Critical Сигма-Тау Индустрие Фармасьютике Риуните С.П.А.
Publication of EA200970877A1 publication Critical patent/EA200970877A1/ru
Publication of EA018442B1 publication Critical patent/EA018442B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к применению ацетил-L-карнитина в сочетании с антигипертензивным лекарственным средством и статином для получения лекарственного средства для предупреждения или задержки начала диабета 2 типа и его осложнений у пациентов с предиабетом с резистентностью к инсулину.
EA200970877A 2007-03-21 2008-03-21 Применение l-карнитина для лечения гипертензии, для снижения систолического или пульсового давления крови у субъектов с предиабетом EA018442B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07104624 2007-03-21
PCT/EP2008/053437 WO2008113862A2 (en) 2007-03-21 2008-03-21 Composition useful for the prevention of type 2 diabetes and its complications in pre-diabetic patients with insulin resistance

Publications (2)

Publication Number Publication Date
EA200970877A1 true EA200970877A1 (ru) 2010-04-30
EA018442B1 EA018442B1 (ru) 2013-08-30

Family

ID=38328657

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970877A EA018442B1 (ru) 2007-03-21 2008-03-21 Применение l-карнитина для лечения гипертензии, для снижения систолического или пульсового давления крови у субъектов с предиабетом

Country Status (24)

Country Link
US (1) US8389574B2 (ru)
EP (1) EP2136798B1 (ru)
JP (2) JP5982091B2 (ru)
KR (1) KR20090120503A (ru)
CN (1) CN101663030B (ru)
AU (1) AU2008228192B2 (ru)
BR (1) BRPI0809034A8 (ru)
CA (1) CA2681185C (ru)
CY (1) CY1116872T1 (ru)
DK (1) DK2136798T3 (ru)
EA (1) EA018442B1 (ru)
ES (1) ES2546619T3 (ru)
HR (1) HRP20150936T1 (ru)
HU (1) HUE025394T2 (ru)
IL (1) IL201014A (ru)
MX (1) MX2009009966A (ru)
MY (1) MY151623A (ru)
NZ (1) NZ579767A (ru)
PL (1) PL2136798T3 (ru)
PT (1) PT2136798E (ru)
SG (2) SG193655A1 (ru)
SI (1) SI2136798T1 (ru)
WO (1) WO2008113862A2 (ru)
ZA (1) ZA200907280B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8589106B2 (en) * 2010-12-22 2013-11-19 Roche Diagnostics Operations, Inc. Calibration of a handheld diabetes managing device that receives data from a continuous glucose monitor
KR20190043076A (ko) * 2017-10-17 2019-04-25 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 당뇨병을 동반한 심혈관계 질환의 예방 또는 치료용 약학 조성물 및 이를 포함하는 복합제제
CN115068451A (zh) * 2021-03-15 2022-09-20 中国医学科学院药物研究所 竹红菌素类化合物作为ltb4受体抑制剂的医药用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670827C3 (de) * 1967-03-20 1974-10-24 Bayer Ag, 5090 Leverkusen 4-(2'-Nitrophenyl)-2,6-dimethyl-3,5-dicarbmethoxy-1,4-dihydropyridin
IT1254314B (it) * 1992-03-27 1995-09-14 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche conyenenti l-carnitina e acil- carnitine inassociazione con ace-inibitori per il trattamento di patologie cardiovascolari.
IT1263004B (it) * 1992-10-08 1996-07-23 Sigma Tau Ind Farmaceuti Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti.
US5925656A (en) * 1995-04-10 1999-07-20 Dr. Reddy's Research Foundation Compounds having antidiabetic, hypolipidemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
IT1290801B1 (it) * 1996-07-05 1998-12-11 Mendes Srl Uso della acetil l-carnitina, della isovaleril l-carnitina, della propionil l-carnitina o dei loro sali farmacologicamente accettabili
IT1293067B1 (it) * 1997-07-01 1999-02-11 Sigma Tau Ind Farmaceuti Composizione farmaceutica per il trattamento di patologie causate da alterato metabolismo lipidico
IT1291113B1 (it) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
US6281234B1 (en) * 1998-05-12 2001-08-28 American Home Products Corporation (2-Acylaminothiazole-4-yl)acetic acid derivative
IT1302289B1 (it) * 1998-09-30 2000-09-05 Univ Catania Composizioni farmaceutiche ad attivita' antineoplastica
CZ20014218A3 (cs) * 1999-06-08 2002-04-17 Sigma-Tau Industrie Farmaceutiche Riunite S. P. A. Antilipemické kombinace obsahující inhibitory HMG-KoA reduktázy a karnitiny
ITRM20010294A1 (it) * 2001-05-29 2002-11-29 Sigma Tau Ind Farmaceuti Uso della acetil l-carnetina in associazione con la biotina per il trattamento di pazienti affetti da diabete mellito di tipo ii insulino re
WO2003028747A1 (en) * 2001-10-04 2003-04-10 Harris Dennis H Ingestible nerve and circulatory nutritional formulation

Also Published As

Publication number Publication date
CN101663030B (zh) 2013-08-21
WO2008113862A3 (en) 2008-12-31
HRP20150936T1 (hr) 2015-09-25
CY1116872T1 (el) 2017-04-05
US20100048691A1 (en) 2010-02-25
DK2136798T3 (en) 2015-08-31
CN101663030A (zh) 2010-03-03
NZ579767A (en) 2012-04-27
SI2136798T1 (sl) 2015-10-30
US8389574B2 (en) 2013-03-05
SG10201507488RA (en) 2015-10-29
BRPI0809034A2 (pt) 2014-10-07
JP2014237717A (ja) 2014-12-18
MY151623A (en) 2014-06-30
PL2136798T3 (pl) 2015-11-30
SG193655A1 (en) 2013-10-30
JP5982091B2 (ja) 2016-08-31
PT2136798E (pt) 2015-10-15
MX2009009966A (es) 2009-10-07
AU2008228192A1 (en) 2008-09-25
JP5974056B2 (ja) 2016-08-23
KR20090120503A (ko) 2009-11-24
WO2008113862A2 (en) 2008-09-25
JP2010521536A (ja) 2010-06-24
IL201014A (en) 2017-06-29
BRPI0809034A8 (pt) 2017-12-26
HK1139040A1 (en) 2010-09-10
ES2546619T3 (es) 2015-09-25
ZA200907280B (en) 2010-06-30
EP2136798A2 (en) 2009-12-30
HUE025394T2 (en) 2016-02-29
EA018442B1 (ru) 2013-08-30
EP2136798B1 (en) 2015-07-29
CA2681185A1 (en) 2008-09-25
IL201014A0 (en) 2010-05-17
CA2681185C (en) 2018-05-01
AU2008228192B2 (en) 2013-02-07

Similar Documents

Publication Publication Date Title
CL2009000173A1 (es) Compuestos derivados de urea-tetrahidroxiquinoxalina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento y la prevencion de la obesidad y la diabetes, resistencia a la insulina, sindrome metabolico, entre otros.
EP2545939A3 (en) Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
WO2008062273A8 (en) Solid oral dosage form having antidiabetic drug combination
IL219915A0 (en) Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
EA201300522A1 (ru) Фармацевтические комбинации для лечения метаболических нарушений
CL2008001125A1 (es) Compuestos derivados de pirimidinona condensada con heterociclos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico y obesidad.
CL2008001126A1 (es) Compuestos derivados de pirimidinona condensada con heterociclos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico y obesidad.
WO2006102610A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
MX2009006709A (es) Tratamiento de enfermedades relacionadas con il-1beta.
CL2006003672A1 (es) Compuestos derivados de pirimido-[4,5-b]-oxazinas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de diabetes mellitus y/u obesidad.
WO2007109182A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2009068708A3 (es) Composición farmacéutica de liberación sostenida de somatostatina o un análogo suyo
WO2004050115A3 (en) Combination treatment using exendin-4 and thiazolidinediones
WO2007109201A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
MX2008004734A (es) Composicion rica en leucina.
MX2009011900A (es) Curacion de herida diabetica.
WO2008079610A3 (en) Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
EA201000392A1 (ru) Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция
WO2007056236A3 (en) Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
MY151623A (en) Composition useful for the prevention of type 2 diabetes and its complications in pre-diabetic patiens with insulin resistance
EA200970798A1 (ru) Композиция для лечения диабета 2 типа
WO2007116428A8 (en) Oral pharmaceutical composition containing cystine or cysteine with glutathione against oxidative stress resulting from haemodialysis
WO2010098625A2 (ko) 약제학적 제제
JP2008189679A5 (ru)
ZA200705349B (en) Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases

Legal Events

Date Code Title Description
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU